Effects of y-24180, a long-acting and potent antagonist to platelet-activating factor, on immediate asthmatic response in guinea pigs

Pharmacology

Volumn 54, Issue 1, 1997, Pages 1-7

  Kagoshima, Masahiko ^a   Tomomatsu, Noriko ^a   Iwahisa, Yoshinori ^a   Yamaguchi, Shuji ^a   Kawakami, Yukio ^a   Terasawa, Michio ^a  

^a Research Laboratories   (Japan)

Author keywords

Asthma; Combined therapy; Guinea Pig; Immediate asthmatic response; PAF antagonist; Y 24180

Indexed keywords

ANTIASTHMATIC AGENT; ANTIHISTAMINIC AGENT; APAFANT; ISRAPAFANT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPYRAMINE; OZAGREL; PRANLUKAST; PROCATEROL; SERATRODAST; THEOPHYLLINE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; ASTHMA; CONTROLLED STUDY; GUINEA PIG; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031050723     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139463     Document Type: Article

References (32)

1. Vargaftig BB. Lcfort J, Chignard M. Benveniste J: Platelel-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. EurJ Pharmacol 1980:65: 185-192.
2. Halonen M, Palmer JD. Lohman IC, McManus LM. Pinckard RN: Respiratory and circulatory alterations induced by acetylglyccryl ether phosphorylcholinc. a mediator of IgE anaphylaxis in the rabbit. Am Rev RcspirDis 1980;122:915-924.
3. Cuss FM, Dixon CMS. Barnes PJ: Effects of inhaled platelet-activating factor on pulmonary function and bronchial responsiveness in man. Lancet 1986: vol ii: 189-192.
4. Chung KF. Aizawa H. Leikauf CD. Uki IF, Evans TW. Nadel JA: Airway hyperresponsiveness induced by platelet-activating factor: Role of thromboxane generation. J Pharmacol ExpTher 1986;236:580-584.
5. Anderson GP. While HL, Fennessy MR: Increased airways responsiveness to histamine induced by platelet-activating factor in the guinea pigs: Possible role of lipoxygenase metabolites. Agents Action 1988:24: 1-7.
6. Morooka S. Uehida M. lmanishi N: Platelel-activating factor (PAF) plays an important role in the immediate asthmatic response in guinea pig by augmenting the response to histamine. Br.1 Pharmacol 1992; 105:756-762.
7. Sirois MG, Lima WT. Fernandes AJB. Johnson RJ, Plante GE. Sirois P: Effect of PAF on rat lung vascular permeability: Role of platelets and polymorphonuclear leukocytes. Br J Pharmacol 1994:111:1111-1116.
8. Evans TW. Chung KF. Rogers DF. Barnes PJ: Effect of platelet-activating factor on airway vascular permeability: Possible mechanisms. J Appl Physiol 1987;63:479-484.
9. Sirois MG. Plante GE. Braquet P. Sirois P: Role of cicosanoids in PAF-induced increases of the vascular permeability in rat airways. Br J Pharmacol 1990:101:896-900.
10. Wardlaw AJ, Moqbcl R, Cromwell O, Kay AB: Platelet-activating factor. A potent chemotactic and che-mokinetic factor for human eosinophils. J Clin Invest 1986:78:1701-1706.
11. Hcnocq E. Vargaftig BB: Accumulation of eosinophils in response to intracutaneous PAF-acether and allergens in man. Lancet 1986; vol i: 1378-1379.
12. Lcllouch-Tubiana A. Lcfort J. Simon M-T, Pfister A. Vargaftig BB: Eosinophil recruitment into guinea pig lungs after PAF-acether and allergen administration. Am Rev Res-pir Dis 1988:137:948-954.
13. Pretolani M, Ferrer-Lopez P. Vargaftig BB: Commentary. From antiasthma drugs to PAF-acether antagonism and back. Biochem Pharmacol 1989;38:1373-1384.
14. Booij-Noord H, Orie NGM. de Vries K: Immediate and late bronchial obstructive reactions to inhalation of house dust and protective effects of disodium cromoglvcate and prednisolone. J Allergy Clin Immunol 1971:48:344-354.
15. Chan-Ycung M. Lam S. Chan H, Tsc KS. Salari H: The release of platelet-activating factor into plasma during allergen-induced bron-choconstriction. J Allergy Clin Immunol 1991;87:667-673.
16. Fitzgerald MF. Moncada S. Parente L: The anaphylactic release of platelet-activating factor from perfused guinea-pig lungs. Br J Pharmacol 1986;88:149-153.
17. Parente L. Fitzgerald MF. Moncada S: Anaphylactic release of plateletactivating factor acether and eicosa-noids from lungs of guinea pigs sensitized to ovalbumin aerosol. Adv Prostaglandin Thromboxane Lcu-kot Res 1987:17:171-176.
18. Terasawa M, Aratani H. Setoguchi M. Tahara T: Pharmacological actions of Y-24180. I. A potent and specific antagonist of platelet-activating factor. Prostaglandins 1990; 40:553-569.
19. Takehara S. Mikashima H. Mura-moto Y. Tcrasawa M. Setoguchi M, Tahara T: Pharmacological actions of Y-24180. a new specific antagonist of platelet-activating factor (PAF). II. Interactions with PAF and benzodiazepine receptors. Prostaglandins 1990:40:571-583.
20. Nambu F. Murakata S. Shiraji T. Omawari N. Sawada M. Okegawa T. Kawasaki A. Ikcda S: OKY-046 inhibits anaphylactic bronchocon-striction and reduces histamine level in bronchoalvcolar lavage fluid in sensitized guinea pigs. Prostaglandins 1990:39:623-637
21. Ashida Y. Matsumoto T, Kuriki H. Shiraishi M, Kato K. Terao S: A novel anti-asthmatic quinone derivative. AA-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids. Prostaglandins 1989:38:91-112.
22. Nakagawa N. Obata T. Kobayashi T. Okada Y. Nambu F, Terawaki T. Aishita H: In vivo pharmacologic profile of ONO-1078: A potent, selective and orally active peptide leu-kotricnc (LT) antagonist. Jpn.J Pharmacol 1992:60:217-225.
23. Iwama T. Komatsu N. Shikada K. Tanaka S: Reversing effect of antiasthmatic drugs on bronchocon-striction induced by antigen challenge and histamine in anesthetized guinea pigs. Jpn J Pharmacol 1992; 58:19-25.
24. Kikkawa H. Kanno K. Ikczawa K: TA-2005. a novel, long-acting, and selective 1-adrenoceptor agonist: Characterization of its in vivo bron-chodilatingaction in guinea pigsand cats in comparison with other T-agonists. Biol Pharm Bull 1994:17: 1047-1052.
25. Shcnficld GM: Combination bron-chodilator therapy. Drugs 1982:24: 414-439.
26. Clark RA. Anderson PB: Combined therapy with salbutamol and be-clomethasonc inhalers in chronic asthma. Lancet 1978: vol ii:70-72.
27. Konzctt II. Rossler R: Versuchs-anordnung zu Untersuchungen an der Bronchialmuskulatur. Naunyn Schmiedebcrgs Arch Pharmacol 1940:195:71-74.
28. Kagoshima M. Tomomatsu N. Aratani H. Terasawa M: Effect of Y-20811. a long-lasting thromboxane A; synthetase inhibitor, on antigen-induced airway hyperresponsivc-ness in guinea pigs. Int Arch Allergy Appl Immunol 1991;96:238-243.
29. Snider GL: The treatment of asthma (editorial). N Engl J Med 1978:298: 397-399.
30. Koch-Weser J. Wcbb-Johnson DC. Andrews JL: Drug therapy: Bron-chodilator therapv. N Engl J Med 1977:297:758-764.
31. Saito M. Fujintura M. Ogawa H. Matsuda T: Role of leukotricncs and platelet-activating factor in allergic bronchoconstriction and their interactions in guinea pig airway in vivo. Prostaglandins Lcukot Essent Fatty Acids 1993:49:579-585.
32. Terashi Y. Yukawa T. Fukuda T. Makino S: Late phase response in the guinea pig airway caliber following inhaled antigen exposure. I. Comparative study of passively and actively sensitized models. Jpn J Al-lcrgol 1988:37:980-991.